The strong evidence from epidemiological studies and clinical trials has confirmed that the efficacy of lipid-lowering drugs can be attributed to genetic and non genetic risk factors. From a genetic perspective, this effect may be related to the genetic polymorphism of lipid-lowering drugs. But there is no clear evidence to verify the significant correlation between gene mutation sites and drug efficacy. Therefore, it is crucial to explore how the genetic polymorphism of lipid-lowering drugs affects blood lipid levels, which in turn affects drug efficacy.
In this project, our goal is to conduct genome-wide association studies (GWAS), whole proteome association studies (PWAS), Mendelian randomization, and advanced statistical techniques such as machine learning algorithms to elucidate the potential genetic mechanisms of disease occurrence and determine the genetic association between drug targets and drug efficacy in lipid related diseases.
